Posted by Michael Wonder on 21 Feb 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of adults with PSMA positive hormone-relapsed metastatic prostate cancer after two or more therapies
21 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of lutetium Lu 177 vipivotide tetraxetan in the NHS in England.
For the time being, Lutetium Lu 177 vipivotide tetraxetan is not recommended for the treatment of adults with prostate specific membrane antigen (PSMA) positive hormone-relapsed metastatic prostate cancer after taxane-based chemotherapy and an anti-androgen or the use of a taxane is medically unsuitable.
